share_log

Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results

Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results

菲爾德Trip Health&Wellness Ltd.報告2023財年第一季度財務和經營業績
GlobeNewswire ·  2022/08/29 17:05
  • Completed corporate reorganization on August 11, 2022 separating the drug development ("Reunion Neuroscience Inc." or "Reunion") and healthcare and wellness ("Field Trip Health & Wellness" or "Field Trip") divisions into two separate public companies (the "Spinout Transaction").
  • Field Trip received listing approval from the TSX Venture Exchange ("TSX-V") and commenced trading on August 17, 2022 under new ticker symbol "FTHW".
  • Concurrent with the closing of the Spinout Transaction, completed a series of private placement financings for gross proceeds of approximately $20 million, led by Oasis Management Company and Reunion, positioning Field Trip to continue to lead this new market.
  • Field Trip generated revenues of $1.8 million during the quarter ended Jun 30, 2022, an increase of 110% over prior year's first fiscal quarter.
  • In May 2022 launched 'Field Trip at Home Powered by Nue Life', an innovative wellness platform for personalized, at-home psychedelic care through providing ketamine treatments, an interactive companion app, and virtual aftercare programs as an alternative to in-clinic care.
  • 於2022年8月11日完成了公司重組,分離了藥物開發(“留尼汪神經科學公司”)。或“團圓”)和醫療保健與健康(“實地考察健康與健康”或“實地考察”)部門合併為兩家獨立的上市公司(“拆分交易”)。
  • 菲爾德Trip獲得了多倫多證券交易所創業板(“TSX-V”)的上市批准,並於2022年8月17日開始交易,新的股票代碼為“FTHW”。
  • 在完成拆分交易的同時,完成了由綠洲管理公司和留尼汪島牽頭的一系列私募融資,總收益約為2000萬美元,使FieldTrip定位為繼續引領這一新市場。
  • 在截至2022年6月30日的季度裏,野外旅行產生了180萬美元的收入,比上一財年第一財季增長了110%。
  • 2022年5月推出了由Nue Life提供動力的家居實地旅行,這是一個創新的健康平臺,通過提供氯胺酮治療、互動同伴應用程序和虛擬後續護理計劃作為診所內護理的替代方案,為個性化的居家迷幻護理提供服務。

TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or "Field Trip"), a global leader in the delivery of psychedelic therapies, reported fiscal first quarter 2023 results for the three-month period ended June 30, 2022, and provided a business update. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

多倫多,2022年8月29日(Global Newswire)--提供迷幻藥物治療的全球領先企業--菲爾德Trip Health&Wellness Ltd.(多倫多證券交易所股票代碼:FTHW)(以下簡稱“公司”或“野外旅行”)公佈了截至2022年6月30日的三個月的2023財年第一季度業績,並提供了業務最新情況。所有業績均根據國際財務報告準則(“國際財務報告準則“)和加元,除非另有説明。

During the quarter, Field Trip continued to deliver innovative psychedelic-assisted therapies across its 12 operating clinics, achieving increased revenue growth of 110% over the prior year's first fiscal quarter. Revenue growth was driven by continued operational improvements, enhanced digital marketing, expanded service offerings and increased conversion of new clients.

在本季度,FieldTrip繼續在其12家運營診所提供創新的迷幻輔助療法,實現了比上一財年第一財季增長110%的收入增長。收入增長是由持續的運營改善、增強的數字營銷、擴大的服務提供和更多的新客户轉換推動的。

To date, Field Trip's focus has been on delivering in-person care through its 12 centres. Over the next twelve months, the Company will expand its focus to offer a blend of both digital and in-clinic experiences, providing a more holistic wellbeing and lifestyle approach to mental health. Through its leading digital psychedelic platform, Field Trip has already created a large, engaged community which provides access to therapies both inside and outside clinical settings. Going forward, Field Trip will leverage the data and learnings from these tools to bring therapies and community support to people at scale.

到目前為止,野外旅行的重點一直是通過其12箇中心提供面對面的護理。在接下來的12個月裏,該公司將擴大其重點,提供數字和臨牀體驗的融合,為精神健康提供更全面的福祉和生活方式。通過其領先的數字迷幻平臺,FieldTrip已經創建了一個大型的參與式社區,提供臨牀環境內外的治療途徑。展望未來,實地旅行將利用這些工具的數據和經驗教訓,為人們帶來大規模的治療和社區支持。

During the quarter, Field Trip launched its 'Field Trip at Home™ Powered by Nue Life' platform, which allows patients to access guided ketamine treatments from the comfort of their home, as an alternative to in-clinic care. Field Trip is now able to provide more convenient and accessible treatment options and will continue to build communities and tools that help to create and sustain lasting wellbeing.

在本季度,FieldTrip推出了由Nue™提供支持的家庭實地旅行平臺,允許患者在舒適的家中獲得有指導的氯胺酮治療,作為臨牀護理的替代方案。實地考察旅行現在能夠提供更方便和可獲得的治療選擇,並將繼續建立社區和工具,幫助創造和維持持久的福祉。

Ronan Levy, Chairman and Chief Executive Officer of Field Trip Health & Wellness, stated, "When we launched Field Trip four years ago, our mission was to trailblaze a path for psychedelic medicine and bring these therapies into the mainstream. We are now happy to say we have achieved that objective. As a standalone company, we plan to lead a whole new approach to mental and emotional health and well-being - one that recognizes that depression and anxiety are not just functions of our brains, but also very much a function of how we live our lives."
Mr. Levy continued, "Going forward, we will build upon our already successful psychedelic-assisted therapy programs at our best-in-class Field Trip Health centers that are generating unparalleled outcomes in depression and anxiety treatments. We are now taking a much more holistic view of mental and emotional health and wellbeing, integrating technology, medicine and community to change how we approach mental health and wellbeing. This multifaceted approach will help people dive into self-discovery and self-awareness, to find their motivations, discover their passions and find the freedom to be happy, connected, free from depression and anxiety and, simply, to be themselves."

野外旅行健康與健康公司董事長兼首席執行官羅南·利維表示:“四年前,當我們推出實地旅行時,我們的使命是開闢一條致幻藥物的道路,並將這些療法帶入主流。現在我們很高興地説,我們已經實現了這一目標。作為一家獨立的公司,我們計劃引領一種全新的心理和情緒健康與福祉方法--認識到抑鬱和焦慮不僅是我們大腦的功能,而且在很大程度上也是我們生活方式的一種功能。”
利維繼續説,“展望未來,我們將在我們一流的野外旅行健康中心開展的迷幻輔助治療項目的基礎上再接再厲,這些項目在抑鬱症和焦慮症的治療方面產生了無與倫比的效果。我們現在對心理和情緒健康與福祉有了更全面的看法,整合了技術、醫學和社區,以改變我們對待心理健康和幸福的方式。這種多方面的方法將幫助人們深入自我發現和自我意識,找到他們的動機,發現他們的激情,找到快樂、相互聯繫、擺脱抑鬱和焦慮的自由,簡單地做他們自己。”

Financial Highlights

財務亮點

Upon closing of the Spinout Transaction, Field Trip held approximately $17.2 million in unrestricted cash.

在Spinout交易完成後,field Trip持有約1720萬美元的無限制現金。

For the fiscal first quarter ended June 30, 2022, the Clinics business generated patient services revenues of $1.8 million from its twelve clinics, representing an increase of 6% over the prior quarter and 110% over the comparative first fiscal quarter of the prior year. The growth in revenue was driven by the addition of six clinics and an increase in the volume of patient visits.

在截至2022年6月30日的第一財季,診所業務從其12家診所產生了180萬美元的患者服務收入,比上一季度增長了6%,比上一財年第一財季增長了110%。收入的增長是由增加了六家診所和病人就診量的增加推動的。

Net loss for the clinics in the first fiscal quarter 2023 was $8.2 million compared with a $9.1 million loss in the same period of the prior fiscal year. This decrease in the net loss was primarily due to a more favorable foreign exchange rate, partly offset by the increase in operating costs associated with operating 12 clinics during the quarter, compared to six clinics in the comparative quarter of the prior fiscal year.

這些診所在2023年第一財季的淨虧損為820萬美元,而上一財年同期的虧損為910萬美元。淨虧損的減少主要是由於匯率更加有利,但與上一會計年度同期的6家診所相比,本季度經營12家診所的運營成本增加部分抵消了這一影響。

Operating expenses for the first fiscal quarter were $12 million, compared to $9.6 million for the prior comparable quarter. This increase was primarily due to $3.4 million in non-recurring costs: $2.4 million in Spinout Transaction costs and a $1.0 million impairment write-off of fixed assets arising from the deferral of future clinic openings.

第一會計季度的營業費用為1200萬美元,而上一可比季度為960萬美元。這一增長主要是由於340萬美元的非經常性成本:240萬美元的拆分交易成本和100萬美元的固定資產減值沖銷,這些減值沖銷是由於推遲未來開設診所而產生的。

"From an operations perspective, we are delighted to report another sequential quarter of revenue growth, while managing to reduce our recurring expenses by 30%," said Mujeeb Jafferi, President of Field Trip Health & Wellness. "We have continued to improve operational efficiencies at our health centres, automate several client acquisition processes and increase community engagement through our digital tools."

“從運營的角度來看,我們很高興又一個季度實現了收入的增長,同時我們設法將經常性開支減少了30%,”野外旅行健康與健康公司的總裁Mujeeb Jafferi説。我們繼續提高我們健康中心的運營效率,實現幾個客户獲取過程的自動化,並通過我們的數字工具增加社區參與度。

Conference Call
The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, August 30, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13732491. A live webcast of the conference call can be accessed via the Events and Presentations section of the Field Trip Health Investor Relations website here.

電話會議
該公司將於2022年8月30日(星期二)上午8:30舉行電話會議和網絡直播,討論其業績。Et.要接聽電話會議,請撥打1-877-407-9716(美國國內)。或1-201-493-6779(美國境外)並提供會議ID 13732491。通過現場旅行健康投資者關係網站的活動和演示部分,可以觀看電話會議的現場網絡直播。

For those unable to attend the live call, a telephonic replay will be available until 11:59 p.m. ET on Tuesday, September, 13 2022. To access the replay dial 1-844-512-2921 (within the U.S.) or 1-412-317-6671 (outside the U.S.) and provide conference ID 13732491. The webcast will be archived and available in the Events and Presentations section of the Field Trip Health Investor Relations website approximately one hour after the conclusion of the live call.

對於那些無法參加現場通話的人,電話重播將持續到晚上11:59。美國東部時間2022年9月13日星期二。要收聽重播,請撥打1-844-512-2921(美國國內)或1-412-317-6671(美國境外)並提供會議ID 13732491。網絡直播將在現場通話結束約一小時後存檔,並在實地旅行健康投資者關係網站的活動和演示部分提供。

Selected Financial Information

精選財務信息

The following table sets forth selected financial information derived from the Company's unaudited combined carve-out financial statements for the fiscal first quarter 2023 ended June 30, 2022, prepared in accordance with IAS 34 in a manner consistent with the Company's annual audited combined carve-out financial statements. The following information should be read in conjunction with the financial statements and management's discussion and analysis, which are available on the Company's website at and under the Company's SEDAR profile at .

下表載列本公司截至2022年6月30日的未經審核綜合分拆財務報表的精選財務資料,該等財務報表是根據國際會計準則第34號以符合本公司年度經審計合併分拆財務報表的方式編制的。以下信息應與財務報表和管理層的討論和分析一起閲讀,這些信息可在公司網站上和公司SEDAR簡介下查閲。

  3 months ended   3 months ended  
  June 30, 2022   June 30, 2021  
  $   $  
Revenue 1,824,404   867,400  
Operating expenses 11,997,250   9,572,710  
Other income (expenses) 1,936,168   (427,924)  
Net loss (8,236,678)   (9,133,235)  
截至3個月 截至3個月
2022年6月30日 2021年6月30日
$ $
收入 1,824,404 867,400
運營費用 11,997,250 9,572,710
其他收入(費用) 1,936,168 (427,924)
淨虧損 (8,236,678) (9,133,235)

About Field Trip Health & Wellness Ltd.

關於野外旅行健康與健康有限公司。

Field Trip Health & Wellness Ltd. is a global leader in psychedelic therapies. With health centres across North America and Europe, along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

菲爾德旅行健康與健康有限公司是迷幻療法的全球領先者。通過北美和歐洲各地的醫療中心,以及將實現大規模規模的數字和技術工具,我們以一種簡單、循證的方式幫助有需要的人,治癒疾病並加強與世界的接觸。

Learn more at and

瞭解更多信息,請訪問和

Follow us on Twitter and Instagram: @fieldtriphealth.

在Twitter和Instagram上關注我們:@fieldtriphealth。

Cautionary Note Regarding Forward-Looking Information

關於前瞻性信息的注意事項

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding the Company and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although the management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to the Company, can be located on the SEDAR website at .

本新聞稿包括有關該公司及其業務的前瞻性信息(符合加拿大證券法和1995年美國私人證券訴訟改革法的定義)。前瞻性信息往往但不總是可以通過使用諸如“預期”、“打算”、“預期”、“相信”或這些詞語和短語的變體(包括負面變體)來確定,或者聲明某些行動、事件或結果“可能”、“可能”、“將”或“將”被採取、發生或實現。這些陳述是基於公司管理層對未來事件的當前預期和看法,是基於假設的,受風險和不確定因素的影響。儘管管理層認為這些陳述所依據的假設是合理的,但它們可能被證明是不正確的。本新聞稿中討論的前瞻性事件和情況可能不會發生,可能會因影響這些公司的已知和未知風險因素和不確定性而大不相同。儘管公司試圖確定可能導致實際行動、事件或結果與前瞻性陳述中描述的大不相同的重要因素,但可能還有其他因素導致行動、事件或結果與預期、估計或預期的不同。因此,讀者不應過分依賴任何前瞻性陳述或信息。任何前瞻性陳述都不能得到保證。除適用的證券法要求外,前瞻性表述僅在作出之日發表,公司不承擔任何公開更新或修改任何前瞻性表述的義務,無論是由於新信息、未來事件或其他原因。有關該公司的更多信息, 可在SEDAR網站上找到。

Neither TSX Venture Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

多倫多證券交易所創業板交易所或其監管服務提供商均未批准本新聞稿的內容,也未對本新聞稿的充分性或準確性承擔責任。

CONTACTS:

聯繫人:

Field Trip Health & Wellness:
Ronan Levy
Chairman & CEO
(416) 505-0929
ronan@fieldtriphealth.com

實地考察健康與健康:
羅南·利維
董事長兼首席執行官
(416) 505-0929
郵箱:ronan@fieldtriphelth.com

Investor contacts:
Phil Carlson / Sophia Bashford
(646) 573-0776) / (929 246-7307)
KCSA Strategic Communications
fieldtripIR@kcsa.com

投資者聯繫方式:
菲爾·卡爾森/索菲亞·巴什福德
(646) 573-0776) / (929 246-7307)
KCSA戰略傳播
郵箱:fieldtripIR@kcsa.com

SOURCE Field Trip Health & Wellness

來源:野外旅行健康與健康


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論